Ascendis Pharma ‘s TransCon PTH can safely treat hypoparathyroidism , reducing the need for other therapies and improving patients’ quality of life, an extension period of the PaTH Forward Phase 2 trial shows.
“Today we announced preliminary clinical results which demonstrate that TransCon PTH can potentially provide a new treatment paradigm for over 150,000 [hypoparathyroidism] patients in...